MX2012013740A - Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina. - Google Patents

Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.

Info

Publication number
MX2012013740A
MX2012013740A MX2012013740A MX2012013740A MX2012013740A MX 2012013740 A MX2012013740 A MX 2012013740A MX 2012013740 A MX2012013740 A MX 2012013740A MX 2012013740 A MX2012013740 A MX 2012013740A MX 2012013740 A MX2012013740 A MX 2012013740A
Authority
MX
Mexico
Prior art keywords
deazaaminopterin
propargyl
methods
methotrexate
treating
Prior art date
Application number
MX2012013740A
Other languages
English (en)
Other versions
MX339793B (es
Inventor
Gijsbertus J Pronk
Original Assignee
Allos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allos Therapeutics Inc filed Critical Allos Therapeutics Inc
Publication of MX2012013740A publication Critical patent/MX2012013740A/es
Publication of MX339793B publication Critical patent/MX339793B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con un método para tratar un trastorno resistente de metotrexato en un individuo, en donde el método comprende la administración al individuo una cantidad efectiva de 10-propargil-10-deazaaminopterin o sus sales farmacéuticamente aceptables.
MX2012013740A 2010-06-02 2011-06-02 Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina. MX339793B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35087110P 2010-06-02 2010-06-02
PCT/US2011/038953 WO2011153368A1 (en) 2010-06-02 2011-06-02 Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin

Publications (2)

Publication Number Publication Date
MX2012013740A true MX2012013740A (es) 2013-07-29
MX339793B MX339793B (es) 2016-06-10

Family

ID=45067077

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013740A MX339793B (es) 2010-06-02 2011-06-02 Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.

Country Status (16)

Country Link
US (1) US20130143891A1 (es)
EP (1) EP2575466B1 (es)
JP (1) JP5897558B2 (es)
KR (1) KR20130115993A (es)
CN (1) CN102984940B (es)
AU (1) AU2011261384B2 (es)
BR (1) BR112012030764A2 (es)
CA (1) CA2800900A1 (es)
DK (1) DK2575466T3 (es)
ES (1) ES2541689T3 (es)
HK (1) HK1179823A1 (es)
IL (1) IL223078A (es)
MX (1) MX339793B (es)
RU (1) RU2586299C2 (es)
WO (1) WO2011153368A1 (es)
ZA (1) ZA201209673B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
ES2596953T3 (es) 2010-02-02 2017-01-13 Allos Therapeutics, Inc. Diastereómeros de 10-propargil-10-desazaaminopterina para uso en el tratamiento del cáncer de pulmón
US20130178441A1 (en) * 2010-08-10 2013-07-11 Allos Therapeutics, Inc. Methods for Extending Progression-Free Survival using 10-Propargyl-10-Deazaaminopterin
WO2013177713A1 (en) * 2012-05-31 2013-12-05 Alphora Research Inc. Process for preparation of an antifolate agent
WO2014020553A1 (en) * 2012-08-03 2014-02-06 Fresenius Kabi Oncology Ltd. Salts of pralatrexate
CN104628727B (zh) * 2013-11-07 2018-08-21 正大天晴药业集团股份有限公司 一种普拉曲沙的晶型及其制备方法
CN104628728A (zh) * 2013-11-08 2015-05-20 深圳海王药业有限公司 一种普拉曲沙的制备方法
CN103588775B (zh) * 2013-11-12 2016-08-17 连云港恒运医药科技有限公司 普拉曲沙降解杂质及其制备方法
CN105272983B (zh) * 2014-06-12 2021-01-15 连云港润众制药有限公司 一种高纯度普拉曲沙固体及其制备方法
CN107488178B (zh) * 2016-06-10 2020-05-12 山东新时代药业有限公司 一种高纯度普拉曲沙中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354751A (en) * 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
WO1993022312A1 (en) * 1992-04-29 1993-11-11 Sri International Deazaaminopterins for treatment of inflammation
ES2313737T3 (es) * 1996-07-17 2009-03-01 Sloan-Kettering Institute For Cancer Research Composiciones purificadas de 10-propargil-10-deazaaminopterina y sus metodos de uso en el tratamiento de tumores.
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
PL1750716T3 (pl) * 2004-05-30 2009-01-30 Sloan Kettering Inst Cancer Res Terapia chłoniaka z komórek t z zastosowaniem 10-propargilo-10-deaza-aminopteryny

Also Published As

Publication number Publication date
JP5897558B2 (ja) 2016-03-30
WO2011153368A1 (en) 2011-12-08
CN102984940A (zh) 2013-03-20
BR112012030764A2 (pt) 2015-09-29
US20130143891A1 (en) 2013-06-06
EP2575466B1 (en) 2015-04-08
AU2011261384B2 (en) 2015-01-22
EP2575466A4 (en) 2013-07-17
DK2575466T3 (en) 2015-07-20
JP2013527245A (ja) 2013-06-27
KR20130115993A (ko) 2013-10-22
EP2575466A1 (en) 2013-04-10
ZA201209673B (en) 2014-03-26
CA2800900A1 (en) 2011-12-08
IL223078A (en) 2016-07-31
RU2586299C2 (ru) 2016-06-10
MX339793B (es) 2016-06-10
HK1179823A1 (en) 2013-10-11
ES2541689T3 (es) 2015-07-23
CN102984940B (zh) 2016-01-13
AU2011261384A1 (en) 2012-12-06
RU2012148767A (ru) 2014-07-20
IL223078A0 (en) 2013-02-03

Similar Documents

Publication Publication Date Title
MX339793B (es) Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.
AU2019268066A1 (en) Methods of treating chronic disorders with complement inhibitors
MY167697A (en) Method for producing 4,4-difluoro-3,4- dihydroisoquinoline derivatives
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
MX360030B (es) Metodos para tratar el trastorno bipolar.
TW201144301A (en) Processes for preparing linezolid
MX362271B (es) Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso.
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
MX2014000515A (es) Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido.
WO2014015056A3 (en) Anti-mucus drugs and uses therefor
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
CA2881554C (en) Methods for inhibiting fascin
WO2012166932A3 (en) Treating tear film disorders with mesenchymal stem cells
MX367811B (es) D-metadona para el tratamiento de síntomas psiquiátricos.
PH12014500990A1 (en) Methods for treating gout flares
MX2015001488A (es) Tratamiento de la inflamacion utilizando serelaxina.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
EP3653607A3 (en) Process for the preparation of enantiomerically enriched 3-aminopiperidine
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX362111B (es) Un metodo para mejorar la funcion hepatica.
WO2012136351A8 (en) Tapentadol for treating pain associated with trigeminal neuralgia
MX355103B (es) Composicion para el tratamiento de desordenes inflamatorios e inmunes.
MX2013006633A (es) Beta-hidroxi-gamma-aminofosfonatos para el tratamiento de trastornos inmunes.

Legal Events

Date Code Title Description
FG Grant or registration